Loading...
Market
FTC approval of Novo Holdings' acquisition of Catalent by end of 2024
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Official FTC announcement or credible news sources
Story
FTC Extends Review of Novo Holdings' $16.5 Billion Catalent Acquisition
May 3, 2024, 03:05 PM
The U.S. Federal Trade Commission (FTC) has issued a second request for more information regarding the $16.5 billion acquisition of Catalent by Novo Nordisk's parent company, Novo Holdings. This move, part of an extended antitrust review, could delay the deal by an additional 30 days. The request reflects the FTC's ongoing scrutiny of the transaction amid concerns from other pharmaceutical groups and contract manufacturers.
View original story
Similar markets
Yes • 50%
No • 50%
Significantly positive • 33%
Moderately positive • 34%
No significant change • 33%
